Annexon, Inc. (ANNX)
$
5.73
+0.10 (1.75%)
Key metrics
Financial statements
Free cash flow per share
-1.1842
Market cap
685.3 Million
Price to sales ratio
0
Debt to equity
0.1669
Current ratio
4.4246
Income quality
0.8523
Average inventory
0
ROE
-0.9228
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Annexon, Inc., a clinical-stage biopharmaceutical company headquartered in Brisbane, California, specializes in uncovering and developing therapeutic solutions for autoimmune, neurodegenerative, and ophthalmic disorders. The total costs and expenses for the company are $154,073,000.00 reflecting its overall spending. With a strategic focus on niche markets, the company achieved a revenue of $0.00 indicating its concentrated approach in specific therapeutic areas. Moreover, the operating income ratio stands at 0.00 illustrating the company's operational profitability margin, while the gross profit ratio is 0.00 which highlights the efficiency of its production and sales operations. The gross profit amounts to -$3,454,000.00 showcasing the company's robust profitability from its core operations. Among its various product candidates, ANX005, a monoclonal antibody, is undergoing Phase II/III clinical trials targeting Guillain-Barré syndrome, as well as a Phase II trial for warm autoimmune hemolytic anemia, and additional studies for Huntington's disease and amyotrophic lateral sclerosis. The company is also advancing ANX009, currently in a Phase Ib trial for lupus nephritis, and ANX007 in Phase II trials aimed at geographic atrophy. Additional investigational products include ANX105, targeting neurodegenerative conditions, and ANX1502, an oral small molecule for specific autoimmune disorders. As a small-cap player with a market capitalization of $685,279,642.00 Annexon is a significant entity in the Biotechnology industry, contributing meaningfully to the overall market landscape. The stock is affordable at $2.86 making it suitable for budget-conscious investors. Furthermore, the stock has a high average trading volume of 2,899,298.00 indicating strong liquidity, which is essential for investors seeking actively traded shares. As a member of the Healthcare sector, Annexon is driving innovation and growth in its field, demonstrating its commitment to enhancing the treatment landscape for patients with challenging medical conditions.
Is Annexon, Inc. (ANNX) a good investment?
Investing in Annexon, Inc. (ANNX) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bearish outlook. Always conduct your own research before investing.
What is Annexon, Inc. (ANNX)'s stock forecast?
Analysts predict Annexon, Inc. stock to fluctuate between $1.29 (low) and $7.18 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Annexon, Inc.'s market capitalization?
As of 2026-02-06, Annexon, Inc.'s market cap is $685,279,642, based on 119,595,051 outstanding shares.
How does Annexon, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Annexon, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Annexon, Inc. (ANNX) stock?
To buy Annexon, Inc. (ANNX) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ANNX. Place an order (Market, Limit, etc.).
What is the best time to invest in Annexon, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Annexon, Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$1.01 | Growth: -42.94%.
Where can I find Annexon, Inc.'s investor relations reports?
Visit https://www.annexonbio.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Annexon, Inc.?
You can explore historical data from here
What is the all-time high and low for Annexon, Inc. stock?
All-time high: $23.61 (2021-09-17) | All-time low: $1.29 (2025-04-10).
What are the key trends affecting Annexon, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
seekingalpha.com
Annexon offers high-risk, high-reward potential with its C1q-targeted pipeline, led by tanruprubart for GBS and vonaprument for geographic atrophy. Tanruprubart's Phase III results are promising, but there is U.S. regulatory uncertainty due to non-U.S. trial sites and dose-response questions. Vonaprument's Phase III trial focuses on vision preservation, potentially differentiating ANNX in the competitive but large geographic atrophy market.
globenewswire.com
BRISBANE, Calif., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on January 9, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4).
seekingalpha.com
Annexon, Inc. (ANNX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
globenewswire.com
BRISBANE, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across life-changing complement-mediated diseases of the body, brain, and eye, today announced that it has granted inducement to a new non-executive employee under the terms of the 2022 Employment Inducement Award Plan. The equity award was approved on December 10, 2025, in accordance with Nasdaq Listing Rule 5635(c)(4).
seekingalpha.com
Annexon Inc. (ANNX) is still a "Buy" in my view, driven by progress in its c1q inhibitor pipeline for rare diseases. ANNX advances tanruprubart for Guillain-Barré syndrome, with an EMA filing planned for January 2026 and ongoing FDA discussions. Vonaprument, targeting dry age-related macular degeneration patients with geographic atrophy, is in phase 3 testing with topline data expected in 2nd half of 2026.
globenewswire.com
BRISBANE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across life-changing complement-mediated diseases of the body, brain, and eye, today announced the pricing of its previously announced underwritten public offering of 25,096,153 shares of its common stock at a price to the public of $2.60 per share and, in lieu of shares of common stock to certain investors, pre-funded warrants to purchase 3,750,000 shares of common stock at a purchase price of $2.599 per share, which equals the public offering price per share of the common stock less the $0.001 exercise price per share of each pre-funded warrant.
seekingalpha.com
Annexon, Inc. (NASDAQ:ANNX ) Wells Fargo 20th Annual Healthcare Conference 2025 September 3, 2025 3:00 PM EDT Company Participants Douglas Love - CEO, President & Director Conference Call Participants Derek Archila - Wells Fargo Securities, LLC, Research Division Presentation Derek Archila Senior Equity Analyst All right, everyone. We'll get to the next fireside here.
seekingalpha.com
Annexon, Inc. (NASDAQ:ANNX ) Cantor Global Healthcare Conference 2025 September 4, 2025 8:00 AM EDT Company Participants Douglas Love - CEO, President & Director Conference Call Participants Pete Stavropoulos - Cantor Fitzgerald & Co., Research Division Presentation Pete Stavropoulos Biotech Analyst So welcome to the Cantor Global Healthcare Conference. I'm Pete Stavropoulos, biotech analyst with Cantor.
globenewswire.com
BRISBANE, Calif., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that it has granted inducement to a new non-executive employee under the terms of the 2022 Employment Inducement Award Plan. The equity award was approved on August 11, 2025, in accordance with Nasdaq Listing Rule 5635(c)(4).
globenewswire.com
New Pilot Appoints Designated Product Development Coordinator to Navigate Regulatory Interactions, Respond to Ad-hoc Queries, and Support Evidence Planning
See all news
